Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has announced the closure of its trading window starting July 1, 2025, in compliance with SEBI's Insider Trading Regulations. The window will remain shut for designated persons and their immediate relatives until 48 hours after the company declares its Unaudited Financial Results for the quarter ended June 30, 2025 (Q1 FY26). The date of the board meeting to approve these results will be communicated to the stock exchanges later. This is a routine compliance measure taken ahead of quarterly results declaration.
This is a standard regulatory compliance announcement with no material impact on shareholders or stock price. It signals that the company is preparing to announce Q1 FY26 results soon, which retail investors should watch for as it may contain important financial updates.